The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Rituximab therapy for myopathy associated with anti–signal recognition particle antibodies: A case series
Open accessAbstract
Objective: The myopathy associated with anti–signal recognition particle (anti‐SRP) is a severe necrotizing immune‐mediated disease characterized by rapidly progressive proximal muscle weakness, markedly elevated serum creatine kinase (CK) levels, and poor responsiveness to traditional immunosuppressive therapies. Reports on the efficacy of B cell depletion therapy for anti‐SRP–associated myopathy are mixed. We describe 8 patients with anti‐SRP–associated myopathy and their response to treatment with the anti‐CD20 monoclonal antibody rituximab. Methods: We identified 8 patients with myopathy who tested positive for anti‐SRP antibodies by immunoprecipitation and were treated with rituximab as part of clinical care. We reviewed their medical records to assess clinical, serologic, and histologic characteristics and response to therapy. In 5 patients, serum was collected before and after rituximab therapy. Autoantibodies were detected by immunoprecipitation and quantitated by densitometry, and the percent decreases in anti‐SRP autoantibody levels were calculated. Results: Six of 8 patients who had been refractory to standard immunosuppressive therapy demonstrated improved manual muscle strength and/or decline in CK levels as early as 2 months after rituximab treatment. Three patients sustained the response for 12–18 months after initial dosing. All of the patients were continued on adjunctive corticosteroids, but doses were substantially reduced after rituximab. Quantitative levels of serum anti‐SRP antibodies also decreased after rituximab treatment. Conclusion: B cell depletion therapy with rituximab is effective for patients with myopathy associated with anti‐SRP. The substantial decrease in anti‐SRP antibody levels after rituximab treatment also suggests that B cells and anti‐SRP antibodies may play a role in the pathogenesis of this myopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Cited by
Dalakas, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1402225 · Cited by 790
Idiopathic inflammatory myopathies
Lundberg, I. E., Fujimoto, M., Vencovsky, J., Aggarwal, R., Holmqvist, M., Christopher-Stine, L., Mammen, A. L., & Miller, F. W. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00321-x · Cited by 703
Self-citationOddis, C. V., Reed, A. M., Aggarwal, R., Rider, L. G., Ascherman, D. P., Levesque, M. C., Barohn, R. J., Feldman, B. M., Harris‐Love, M. O., Koontz, D. C., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37754 · Cited by 701
224th ENMC International Workshop:
Allenbach, Y., Mammen, A. L., Benveniste, O., Stenzel, W., Allenbach, Y., Amato, A., Aussey, A., Benveniste, O., De Bleecker, J., de Groot, I., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.09.016 · Cited by 582
Self-citationImmune-mediated necrotizing myopathy: clinical features and pathogenesis
Allenbach, Y., Benveniste, O., Stenzel, W., & Boyer, O. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00515-9 · Cited by 335
Metadata
- Authors
- Valiyil, R., Casciola‐Rosen, L., Hong, G., Mammen, A., & Christopher‐Stine, L.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2010-09
- Volume
- 62
- Issue
- 9
- Pages
- 1328-1334
- ISSN
- 0893-7524 (ISSN-L)
- 2151-464X
- 2151-4658
- OpenAlex
- W1982008427
- Cited by
- 236
- References
- 1
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.